ABSTRACT
The COVID-19 pandemic has left a legacy in the management of health emergencies, but sentinel surveillance was relatively underused, despite its significant role in decision-making during epidemics. Here we describe a sentinel SARS-CoV-2 antigens’ serosurveillance carried out on a cohort of 395 individuals at a Brazilian institution, from October 2020 to December 2022. A total of 1,507 serum samples were analyzed for IgG and IgA against SARS-CoV-2 Spike (S) or nucleocapsid (N) proteins, in the pre- and post-vaccination periods. The latter included two doses of CoronaVac (group 1, G1), or ChAdOx-1 or BNT162b2 (group 2, G2), followed by heterologous booster doses. In the pre-vaccination phase, 26.5% of participants showed IgG positivity for S and 13.7% for N. After the vaccines’ first dose, S IgG response was positive in 66.6% or 98% of G1 or G2 participants, respectively, while 100% of the participants showed S IgG positivity after the second dose, and S IgG and IgA after the booster. This initiative enabled the examination of viral transmission beyond hospital environments, which is rarely explored in existing literature, and established protocols for managing future emergencies. In addition, a serum bank and a comprehensive database were established, now available to the scientific community.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Brazil [grant numbers E-26/211.128/2021, E-26/201.173/2021]; and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil [grant number 312650/2021-3].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The local ethics committee in research (CEP - Comite de etica em pesqisa) of Hospital Universitario Clementino Fraga Filho / Universidade Federal do Rio de Janeiro (HUCFF/UFRJ) gave ethical approval for this work (n 35.303.120.5.0000.5257).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
